Veracyte Inc Equity-NMS: VCYT

Healthcare

Diagnostics & Research

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$41
Open :	$41.15
Today's high :	$42.1
Today's low :	$40.29
52W low :	$22.61
52W high :	$50.71
1Y :	-3.62%
5Y :	-21.32%
EPS(TTM): :	0.38
Shares O/S :	79.05 M
Market cap :	3.29 B

What is the share price of Veracyte Inc today?

Veracyte Inc (VCYT) share price as of January 19, 2026, is $41.57. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Veracyte Inc?

Yes, Indian Investors can invest in the Veracyte Inc (VCYT) Share by opening an international trading account with Angel One.

How can I purchase Veracyte Inc shares in India?

Purchasing Veracyte Inc (VCYT) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Veracyte Inc (VCYT) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Veracyte Inc?

Yes, you can purchase fractional shares of Veracyte Inc (VCYT) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Veracyte Inc?

The market capitalization of Veracyte Inc on January 19, 2026, is $3.29 B.

In which sector Veracyte Inc belongs?

Veracyte Inc operates in the Healthcare sector, specifically in the Diagnostics & Research industry.

What documents are required to invest in Veracyte Inc stocks?

In order to invest in Veracyte Inc (VCYT) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.